{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:53:34Z","timestamp":1790553214581,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s11892-019-1123-8","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T09:03:59Z","timestamp":1549530239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Mineralocorticoid Antagonism and Diabetic Kidney Disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Yuliya","family":"Lytvyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas C.","family":"Godoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie A.","family":"Scholtes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"1123_CR1","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chang AR, Cheng S, Chiuve SE, et al. Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association. 2018."},{"key":"1123_CR2","unstructured":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet (London, England). 2016;387(10027):1513\u201330."},{"issue":"10","key":"1123_CR3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1681\/ASN.2013091004","volume":"25","author":"IH Boer de","year":"2014","unstructured":"de Boer IH, Afkarian M, Rue TC, Cleary PA, Lachin JM, Molitch ME, et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2014;25(10):2342\u201350.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1123_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2337\/dc15-2322","volume":"39","author":"MG Wong","year":"2016","unstructured":"Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016;39(5):694\u2013700.","journal-title":"Diabetes Care"},{"key":"1123_CR5","doi-asserted-by":"crossref","unstructured":"The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. Controlled clinical trials. 2003;24(4):442\u201361.","DOI":"10.1016\/S0197-2456(03)00028-X"},{"issue":"3","key":"1123_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/MNH.0000000000000214","volume":"25","author":"Y Lytvyn","year":"2016","unstructured":"Lytvyn Y, Bjornstad P, Pun N, Cherney DZ. New and old agents in the management of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2016;25(3):232\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"Suppl 1","key":"1123_CR7","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1016\/j.jcjd.2017.11.004","volume":"42","author":"P McFarlane","year":"2018","unstructured":"McFarlane P, Cherney D, Gilbert RE, Senior P. Chronic kidney disease in diabetes. Can J Diabetes. 2018;42(Suppl 1):S201\u2013s9.","journal-title":"Can J Diabetes"},{"issue":"19","key":"1123_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941\u201351.","journal-title":"N Engl J Med"},{"issue":"12","key":"1123_CR9","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1681\/ASN.2006060560","volume":"17","author":"P Ruggenenti","year":"2006","unstructured":"Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol: JASN. 2006;17(12):3472\u201381.","journal-title":"J Am Soc Nephrol: JASN"},{"issue":"9590","key":"1123_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet (London, England). 2007;370(9590):829\u201340.","journal-title":"Lancet (London, England)"},{"issue":"10","key":"1123_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907\u201317.","journal-title":"N Engl J Med"},{"issue":"4","key":"1123_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00125-009-1268-0","volume":"52","author":"GM Magee","year":"2009","unstructured":"Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009;52(4):691\u20137.","journal-title":"Diabetologia"},{"issue":"12","key":"1123_CR13","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"1123_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"12","key":"1123_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"1123_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30\u201348.","journal-title":"Ann Intern Med"},{"issue":"15","key":"1123_CR17","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547\u201359.","journal-title":"N Engl J Med"},{"issue":"9638","key":"1123_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (London, England). 2008;372(9638):547\u201353.","journal-title":"Lancet (London, England)"},{"issue":"20","key":"1123_CR19","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892\u2013903.","journal-title":"N Engl J Med"},{"issue":"23","key":"1123_CR20","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204\u201313.","journal-title":"N Engl J Med"},{"key":"1123_CR21","doi-asserted-by":"crossref","unstructured":"Microvascular Complications and Foot Care: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S105-s18.","DOI":"10.2337\/dc18-S010"},{"key":"1123_CR22","doi-asserted-by":"crossref","unstructured":"KDOQI clinical practice guideline for diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60(5):850\u201386.","DOI":"10.1053\/j.ajkd.2012.07.005"},{"issue":"5","key":"1123_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nrneph.2015.30","volume":"11","author":"AH Danser","year":"2015","unstructured":"Danser AH, van den Meiracker AH. Heart failure: new data do not SUPPORT triple RAAS blockade. Nat Rev Nephrol. 2015;11(5):260\u20132.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"1123_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11906-005-0012-5","volume":"7","author":"P Magni","year":"2005","unstructured":"Magni P, Motta M. Aldosterone receptor antagonists: biology and novel therapeutic applications. Curr Hypertens Rep. 2005;7(3):206\u201311.","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"1123_CR25","first-page":"41","volume":"61","author":"M Lombes","year":"2000","unstructured":"Lombes M, Farman N, Bonvalet JP, Zennaro MC. Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol (Paris). 2000;61(1):41\u20136.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"12","key":"1123_CR26","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/cvr\/28.12.1863","volume":"28","author":"MJ Fullerton","year":"1994","unstructured":"Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 1994;28(12):1863\u20137.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"1123_CR27","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141(10):3871\u20138.","journal-title":"Endocrinology"},{"issue":"4","key":"1123_CR28","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98(4):1063\u20138.","journal-title":"J Clin Invest"},{"issue":"1 Pt 2","key":"1123_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999;33(1 Pt 2):232\u20137.","journal-title":"Hypertension"},{"issue":"1","key":"1123_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","volume":"66","author":"NK Hollenberg","year":"2004","unstructured":"Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66(1):1\u20139.","journal-title":"Kidney Int"},{"issue":"2","key":"1123_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","volume":"166","author":"P Romagni","year":"2003","unstructured":"Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis. 2003;166(2):345\u20139.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1123_CR32","doi-asserted-by":"publisher","first-page":"R994","DOI":"10.1152\/ajpregu.90903.2008","volume":"296","author":"BS Huang","year":"2009","unstructured":"Huang BS, White RA, Jeng AY, Leenen FH. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R994\u2013R1000.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"9","key":"1123_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486\u201392.","journal-title":"Nat Clin Pract Nephrol"},{"issue":"1","key":"1123_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/147323000102900103","volume":"29","author":"A Sato","year":"2001","unstructured":"Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29(1):13\u201321.","journal-title":"J Int Med Res"},{"issue":"6","key":"1123_CR35","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/0002-9149(82)90390-3","volume":"49","author":"P Lijnen","year":"1982","unstructured":"Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol. 1982;49(6):1561\u20133.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1123_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"J Staessen","year":"1981","unstructured":"Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91(3):457\u201365.","journal-title":"J Endocrinol"},{"issue":"10","key":"1123_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"1","key":"1123_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1071-9164(96)80009-1","volume":"2","author":"AD Struthers","year":"1996","unstructured":"Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2(1):47\u201354.","journal-title":"J Card Fail"},{"issue":"1","key":"1123_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/j.1552-4604.1993.tb03901.x","volume":"33","author":"C Borghi","year":"1993","unstructured":"Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993;33(1):40\u20135.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1123_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41(1):64\u20138.","journal-title":"Hypertension"},{"issue":"11","key":"1123_CR41","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"KJ Schjoedt","year":"2004","unstructured":"Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47(11):1936\u20139.","journal-title":"Diabetologia"},{"issue":"4","key":"1123_CR42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","volume":"56","author":"MG Saklayen","year":"2008","unstructured":"Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008;56(4):714\u20139.","journal-title":"J Investig Med"},{"issue":"2","key":"1123_CR43","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"A Chrysostomou","year":"2006","unstructured":"Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol: CJASN. 2006;1(2):256\u201362.","journal-title":"Clin J Am Soc Nephrol: CJASN."},{"issue":"9","key":"1123_CR44","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"K Rossing","year":"2005","unstructured":"Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28(9):2106\u201312.","journal-title":"Diabetes Care"},{"issue":"6","key":"1123_CR45","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68(6):2829\u201336.","journal-title":"Kidney Int"},{"issue":"3","key":"1123_CR46","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70(3):536\u201342.","journal-title":"Kidney Int"},{"issue":"12","key":"1123_CR47","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70(12):2116\u201323.","journal-title":"Kidney Int"},{"issue":"1","key":"1123_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1291\/hypres.31.59","volume":"31","author":"Y Furumatsu","year":"2008","unstructured":"Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31(1):59\u201367.","journal-title":"Hypertens Res"},{"issue":"9","key":"1123_CR49","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/08860220903150312","volume":"31","author":"I Guney","year":"2009","unstructured":"Guney I, Selcuk NY, Altintepe L, Atalay H, Basarali MK, Buyukbas S. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail. 2009;31(9):779\u201384.","journal-title":"Ren Fail"},{"issue":"2","key":"1123_CR50","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/ndt\/gfs429","volume":"28","author":"E Morales","year":"2013","unstructured":"Morales E, Millet VG, Rojas-Rivera J, Huerta A, Gutierrez E, Gutierrez-Solis E, et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant. 2013;28(2):405\u201312.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1123_CR51","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol: CJASN. 2006;1(5):940\u201351.","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"key":"1123_CR52","volume":"4","author":"D Bolignano","year":"2014","unstructured":"Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1123_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"AS Bomback","year":"2008","unstructured":"Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51(2):199\u2013211.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1123_CR54","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jdi.12629","volume":"8","author":"LJ Sun","year":"2017","unstructured":"Sun LJ, Sun YN, Shan JP, Jiang GR. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy. J Diabetes Investig. 2017;8(4):609\u201318.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"1123_CR55","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","volume":"52","author":"L Tylicki","year":"2008","unstructured":"Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52(3):486\u201393.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1123_CR56","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/sj.ki.5002511","volume":"72","author":"L Tylicki","year":"2007","unstructured":"Tylicki L, Rutkowski P, Renke M, Rutkowski B. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney Int. 2007;72(9):1164\u20135.","journal-title":"Kidney Int"},{"key":"1123_CR57","doi-asserted-by":"crossref","unstructured":"Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension. 69(5):870\u20138.","DOI":"10.1161\/HYPERTENSIONAHA.116.08526"},{"key":"1123_CR58","doi-asserted-by":"crossref","unstructured":"Barrera-Chimal J, Andre-Gregoire G, Nguyen Dinh Cat A, Lechner SM, Cau J, Prince S, et al. Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1. J Am Soc Nephrol. 28(4):1216\u201326.","DOI":"10.1681\/ASN.2016040477"},{"issue":"14","key":"1123_CR59","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"1123_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","volume":"24","author":"P Kolkhof","year":"2015","unstructured":"Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015;24(5):417\u201324.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"1123_CR61","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/jcph.865","volume":"57","author":"EB Wang","year":"2017","unstructured":"Wang EB, Chaudhary A, Waterhouse TH, Dickinson GL. Population pharmacokinetics of LY2623091 in patients with hypertension and chronic kidney disease. J Clin Pharmacol. 2017;57(6):739\u201346.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1123_CR62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ejhf.444","volume":"18","author":"P Bramlage","year":"2016","unstructured":"Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016;18(1):28\u201337.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"1123_CR63","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/FJC.0000000000000126","volume":"64","author":"E Bisping","year":"2014","unstructured":"Bisping E, Wakula P, Poteser M, Heinzel FR. Targeting cardiac hypertrophy: toward a causal heart failure therapy. J Cardiovasc Pharmacol. 2014;64(4):293\u2013305.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1123_CR64","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fphar.2013.00115","volume":"4","author":"S Orena","year":"2013","unstructured":"Orena S, Maurer TS, She L, Eudy R, Bernardo V, Dash D, et al. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol. 2013;4:115.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1123_CR65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1123_CR66","doi-asserted-by":"crossref","unstructured":"Bonnard B, Pieronne-Deperrois M, Djerada Z, Elmoghrabi S, Kolkhof P, Ouvrard-Pascaud A, et al. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J Mol Cell Cardiol. 121:124\u201333.","DOI":"10.1016\/j.yjmcc.2018.06.008"},{"key":"1123_CR67","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 37(27):2105\u201314. Results of the phase-2 minerAlocorticoid Receptor Antagonist Tolerability Study (ARTS) in patients with heart failure showed a decreased risk of side effect and potential for albuminuria reduction with novel MRA agent, finerenone when compared to spironolactone.","DOI":"10.1093\/eurheartj\/ehw132"},{"key":"1123_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271\u2013305.","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"1123_CR69","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ejhf.218","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease. Eur J Heart Fail. 2015;17(2):224\u201332.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1123_CR70","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","volume":"14","author":"B Pitt","year":"2012","unstructured":"Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14(6):668\u201375.","journal-title":"Eur J Heart Fail"},{"issue":"31","key":"1123_CR71","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"key":"1123_CR72","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394. This study provides evidence that treating T2D patients with albuminuria and eGFR >30 ml\/min\/1.73m\n                              2 with finerenone for 90\u00a0days reduces albuminuria without side effects associated with older MRA agents.","DOI":"10.1001\/jama.2015.10081"},{"issue":"3","key":"1123_CR73","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes. Am J Nephrol. 2017;46(3):213\u201321.","journal-title":"Am J Nephrol"},{"issue":"2","key":"1123_CR74","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M547","volume":"45","author":"P Goutorbe","year":"2011","unstructured":"Goutorbe P, Montcriol A, Lacroix G, Bordes J, Meaudre E, Souraud JB. Intestinal necrosis associated with orally administered calcium polystyrene sulfonate without sorbitol. Ann Pharmacother. 2011;45(2):e13.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1123_CR75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"12","key":"1123_CR76","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1161\/hq1201.100226","volume":"21","author":"S Meaume","year":"2001","unstructured":"Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol. 2001;21(12):2046\u201350.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1123_CR77","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674\u201384.","journal-title":"JAMA"},{"issue":"21","key":"1123_CR78","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223\u201333.","journal-title":"JAMA"},{"key":"1123_CR79","first-page":"817","volume-title":"Brenner and Rector\u2019s the kidney","author":"J Miller","year":"1996","unstructured":"Miller J, Tobe S, Skorecki K. Control of extracellular fluid volume and the pathophysiology of edema formation. In: Brenner B, editor. Brenner and Rector\u2019s the kidney. I. 5th ed. Philadelphia: WB Saunders; 1996. p. 817\u201372.","edition":"I. 5th"},{"issue":"4","key":"1123_CR80","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"7","key":"1123_CR81","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"key":"1123_CR82","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1812389\n                      \n                    .","DOI":"10.1056\/NEJMoa1812389"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1123-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-019-1123-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1123-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:32:38Z","timestamp":1579739558000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-019-1123-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1007\/s11892-019-1123-8","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"23 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Yuliya Lytvyn, Lucas C. Godoy, and Rosalie A. Scholtes declare that they have no conflict of interest.Dani\u00ebl H. van Raalte receives research funding from AstraZeneca, Boehringer Ingelheim, Merck, and Sanofi. He has received consulting fees and\/or speaking honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, and Sanofi. All honoraria are directly transferred to the employer (AUMC).David Z. Cherney receives operating funds from Boehringer Ingelheim, Janssen, AstraZeneca, and Merck. He has received consulting fees and\/or speaking honoraria from Boehringer Ingelheim, Janssen, AstraZeneca, Merck, Mitsubishi-Tanabe, Sanofi, Bayer, Prometic, and Abbvie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"4"}}